clinicaltrial
-
New Trial Data Is Strongest Yet for Any Experimental Alzheimer’s Drug
New clinical trial data released by Eli Lilly on Wednesday has provided the most promising results of any potential Alzheimer’s disease treatment yet. In a randomised, double-blinded, controlled phase III trial, the experimental drug donanemab significantly slowed cognitive decline in patients compared to placebo, with nearly half of those on the drug experiencing no decline…
-
U.S. FDA Approves New Alzheimer’s Drug, but There Are Lingering Questions
The Food and Drug Administration on Friday granted the conditional approval of a new treatment for people with early Alzheimer’s disease: the antibody-based drug lecanemab, jointly developed by the pharmaceutical companies Biogen and Eisai. In a large trial, lecanemab appeared to slow down patients’ cognitive decline relative to those on placebo. But some experts and…
